Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

According to Spherix Global Insights, US rheumatologists are most likely to prefer Bimzelx’s dual IL-17A/F pathway as the most efficacious of all interleukins available in PsA. EXTON, PA, April 16, 2024 — In October of 2023, the US FDA approved Novartis’ intravenous formulation of Cosentyx for